CMG MedSource Book a Free Call Home›Resources›Peptide Therapy Sourcing Peptide Sourcing Compounded Peptide Therapy: Sourcing, Compliance, and Clinical Use CMG MedSource September 2026 10 min read Peptide therapy has become a core offering at longevity clinics, men's health practices, sports medicine centers, and medical spas. But the regulatory landscape for compounded peptides has shifted significantly since 2023, and sourcing them compliantly requires a clear understanding of which peptides remain available, from what type of facility, and under what legal framework. Regulatory status changes frequently: The FDA has taken regulatory action affecting multiple commonly compounded peptides since 2023, including BPC-157, ipamorelin, CJC-1295, and others. Confirm current availability and legal sourcing authority with a healthcare compliance attorney before establishing or expanding a peptide program. CMG MedSource can connect you with current sourcing options based on what is actively available from compliant pharmacy partners. What Are Compounded Peptides? Peptides are short chains of amino acids (typically 2 to 50 amino acids) that function as signaling molecules in the body. Unlike large protein biologics, peptides are small enough to be synthesized chemically or derived from biological sources, and many can be administered via subcutaneous injection. In clinical compounding, peptides are prepared by licensed pharmacies using pharmaceutical-grade active pharmaceutical ingredients (APIs), combined with appropriate diluents, stabilizers, and preservatives. The resulting preparation is typically a sterile injectable vial or pre-filled syringe. Because most therapeutic peptides are not FDA-approved drug products, they are only accessible through licensed compounding pharmacies under applicable compounding authority. Common Clinical Peptide Categories Peptide(s) Clinical Application Regulatory Notes Ipamorelin, CJC-1295, Sermorelin Growth hormone secretagogues; body composition, recovery Subject to FDA action 2023-2024; verify current status BPC-157 Tissue repair, gut healing, tendon/ligament recovery FDA 2023 guidance raised compounding concerns; verify PT-141 (Bremelanotide) Sexual dysfunction FDA-approved as Vyleesi; compounded copies may be restricted Thymosin Alpha-1 (Ta1) Immune modulation, chronic illness Not FDA-approved; compounding status varies TB-500 (Thymosin Beta-4 fragment) Injury recovery, inflammation Not FDA-approved; verify current pharmacy availability Kisspeptin, AOD-9604, MOTS-c Hormonal, metabolic, mitochondrial support Emerging; regulatory status varies by compound Glutathione (IV/injectable) Antioxidant, detoxification, skin brightening Widely compounded; verify pharmacy USP 797 compliance Table reflects general status as of late 2025. Regulatory status changes; verify with current sources before ordering. The FDA and Compounded Peptides: What Changed In 2023, the FDA published guidance clarifying that certain substances, including some peptides, fall under the category of "biological products" rather than drugs, which affects compounding authority under Section 503A and 503B. Additionally, the agency identified several peptides as "essentially a copy" of FDA-approved drugs (like bremelanotide/Vyleesi), limiting compounding of those specific molecules. The FDA also added several commonly compounded peptides to a list of substances that may not be compounded under 503A, citing safety concerns and lack of clinical evidence supporting their use in the compounding context. This affected availability from many pharmacies. The result: the peptide sourcing landscape today requires more due diligence than it did in 2021 or 2022. Availability varies by compound, by pharmacy, and by the specific regulatory pathway the pharmacy is relying on. Sourcing Compounded Peptides Compliantly Use Licensed, Accredited Pharmacies All compounded peptides should be sourced from state-licensed pharmacies operating under current USP 797 standards for sterile preparations. For injectable peptides, sterility testing is not optional. PCAB accreditation (Pharmacy Compounding Accreditation Board) is a meaningful quality indicator for 503A pharmacies. Require Certificates of Analysis Every batch of compounded injectable peptides should come with a batch-specific certificate of analysis (COA) documenting testing for identity (confirming the active ingredient is what it claims to be), potency (concentration is within specification), sterility, endotoxin levels, and particulate matter. Pharmacies that cannot or will not provide COAs should not be used. Verify API Source The API used to compound peptides should come from a licensed, registered API manufacturer. Research-grade peptides from unregistered chemical suppliers are not appropriate for clinical use, and some pharmacies have been found to use non-pharmaceutical-grade starting materials. Ask your pharmacy to document the source of their APIs. Red flag: Any pharmacy unwilling to provide certificates of analysis, disclose their API source, or produce documentation of their state pharmacy license and compounding accreditation should not be used as a clinical supplier, regardless of price or convenience. Clinical Documentation Requirements For any compounded peptide program, maintain the following per patient: Written informed consent disclosing the compounded, non-FDA-approved nature of the preparation Clinical indication documented in the patient record Prescribing provider's license and DEA registration on file Pharmacy COA for each lot received and administered Patient monitoring and follow-up documentation Frequently Asked Questions What peptides can be legally compounded for clinical use? The list of legally compoundable peptides has changed in recent years. As of 2026, availability depends on the specific peptide, the pharmacy's compounding authority, and current FDA regulatory positions. Some peptides that were widely available in 2021-2022 are now subject to restrictions or enforcement. Confirm availability and legal status for each specific peptide with your pharmacy partner and a compliance attorney. How do longevity clinics source peptide therapy? Longevity clinics typically work with one or more 503A compounding pharmacies that specialize in sterile injectables. Prescribers write patient-specific prescriptions; the pharmacy compounds and ships to the clinic or directly to the patient. For clinics with high volume, a pharmaceutical sourcing partner can simplify the process of identifying and vetting pharmacy options, ensuring quality standards are met, and maintaining compliance documentation. Do I need a DEA license to prescribe peptides? Most compounded peptides are not DEA-scheduled substances, so a DEA registration is not specifically required for peptides. However, a valid DEA registration is required for any controlled substances in your formulary, and some pharmacy credentialing processes request it regardless. Verify with your pharmacy partner what credentials they require for onboarding. What is the difference between research-grade and pharmaceutical-grade peptides? Research-grade peptides are produced for laboratory use, not for human administration. They are not manufactured under pharmaceutical GMP standards, may not meet purity specifications for injection, and are not appropriate for clinical use in patients. Pharmaceutical-grade peptide APIs are produced by licensed API manufacturers to pharmacopoeia specifications. All compounded peptides used in clinical settings must be made from pharmaceutical-grade APIs. How do I evaluate a compounding pharmacy for peptide sourcing? Evaluate: valid state pharmacy license and PCAB accreditation, documented USP 797 compliance for sterile preparations, batch-specific COAs with identity and potency testing from a third-party lab, disclosed pharmaceutical-grade API sourcing, a clean regulatory history (no FDA warning letters related to sterility or adulteration), and the ability to articulate the regulatory basis for compounding each specific peptide you intend to order. Sourcing Peptides for Your Clinic? CMG MedSource connects longevity clinics, med spas, and wellness practices with vetted, compliant compounding pharmacy partners. Free sourcing consultation for licensed providers. Book a Free 15-Minute Call Related articles: 503A vs. 503B Compounding: What Healthcare Providers Need to Know GLP-1 Compounding for Medical Practices: A Provider's Guide What Is a Pharmaceutical Sourcing Partner and Do You Need One? Home info@cmgmedsource.com Schedule a Call CMG MedSource | Dallas, Texas | Pharmaceutical Sourcing for Licensed Providers This content is for informational purposes only and does not constitute legal or regulatory advice. Regulatory status for compounded peptides is subject to ongoing change. Consult a qualified healthcare compliance attorney for current guidance.